ArticleMolecular cancer therapeutics2020
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Genome-wide methylation analysis of circulating cell-free DNA identifies an episignature in lung cancer: validation of EMP2 as a potential biomarker.Clinical epigenetics · 2025Article
- GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth.Journal for immunotherapy of cancer · 2024Article
- The Multifaceted Role of Epithelial Membrane Protein 2 in Cancer: from Biomarker to Therapeutic Target.Biomolecules & therapeutics · 2024Review
- EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer.Cancers · 2024Article
- Sensitization of cancer cells to ferroptosis coincident with cell cycle arrest.Cell chemical biology · 2024Article
- Review
- Comprehensive RNA-seq profiling to evaluate the rabbit mammary gland transcriptome after mastitis.Journal of animal science · 2023Article
- Underlying mechanisms and clinical potential of circRNAs in glioblastoma.Oncology research · 2023Review
- Epithelial membrane protein 2 (EMP2) regulates hypoxia-induced angiogenesis in the adult retinal pigment epithelial cell lines.Scientific reports · 2022Article
- Article
- SHMT2 Induces Stemness and Progression of Head and Neck Cancer.International journal of molecular sciences · 2022Article
- Network-based inference of master regulators in epithelial membrane protein 2-treated human RPE cells.BMC genomic data · 2022Article
- circRNA-0002109 promotes glioma malignant progression via modulating the miR-129-5P/EMP2 axis.Molecular therapy. Nucleic acids · 2022Article
- Role of EMP2 and Del-1 in Tamoxifen-resistant Breast Cancer Cells.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Christen DillardDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Meagan KiyoharaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Vei MahDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Sean P McDermottDepartment of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.
Dana BazzounDepartment of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.
Jessica TsuiDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Ann M ChanDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Ghassan HaddadDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0002-0708-3545
Matteo PellegriniDepartment of Molecular, Cell & Developmental Biology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Yu-Ling ChangDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0002-0789-4989
Yahya ElshimaliCenter to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.
Yanyuan WuCenter to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.
Jaydutt V VadgamaCenter to Eliminate Cancer Health Disparities, Charles Drew University, Los Angeles, CA.
Sara R KimDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Lee GoodglickDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Samuel M LawDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Deven D PatelDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.ORCID 0000-0003-4417-5913
Puneet DhawanDepartment of Surgery, Harbor UCLA, Torrance, CA.
Neil A O'BrienDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Lynn K GordonDepartment of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Jonathan BraunDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Gary LazarDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Max S WichaDepartment of Internal Medicine-Hematology/Oncology, University of Michigan, Ann Arbor, MI.
Madhuri WadehraDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. mwadehra@mednet.ucla.edu.
University of California, Los Angeles · USCharles R. Drew University of Medicine and Science · USUniversity of Michigan · USUCLA Medical Center · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MVirology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MSupporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7MTraining and Mentoring ProgramsU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIETRAS, RICHARD JOSEPH · 2009 to 2020
$7.5MTargeting breast cancer stem cellsR35CA197585 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WICHA, MAX S. · 2016 to 2022
$6.4MUsing EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6MNCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA163971NCI NIH HHS R35 CA197585NCI NIH HHS U54 CA143930NCI NIH HHS U54 CA143931NIAID NIH HHS P30 AI028697
Abstract
Little is known about the role of epithelial membrane protein-2 (EMP2) in breast cancer development or progression. In this study, we tested the hypothesis that EMP2 may regulate the formation or self-renewal of breast cancer stem cells (BCSC) in the tumor microenvironment.
Indexed as
Gene Expression Regulation, NeoplasticAnimalsAntibodies, MonoclonalApoptosisBiomarkers, TumorBreast NeoplasmsCell ProliferationEpithelial-Mesenchymal TransitionFemaleHumansMembrane GlycoproteinsMiceMice, Inbred BALB CMice, NudeNeoplasm MetastasisNeoplastic Stem CellsAntibodies, MonoclonalBiomarkers, TumorEMP2 protein, humanMembrane Glycoproteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.